Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Karyopharm Therapeutics (KPTI) Gross Profit (2019 - 2025)

Historic Gross Profit for Karyopharm Therapeutics (KPTI) over the last 6 years, with Q4 2025 value amounting to $32.6 million.

  • Karyopharm Therapeutics' Gross Profit rose 1158.47% to $32.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $140.1 million, marking a year-over-year increase of 63.78%. This contributed to the annual value of $140.1 million for FY2025, which is 63.78% up from last year.
  • Latest data reveals that Karyopharm Therapeutics reported Gross Profit of $32.6 million as of Q4 2025, which was up 1158.47% from $41.9 million recorded in Q3 2025.
  • In the past 5 years, Karyopharm Therapeutics' Gross Profit ranged from a high of $125.5 million in Q4 2021 and a low of $21.5 million during Q2 2021
  • Moreover, its 5-year median value for Gross Profit was $36.4 million (2023), whereas its average is $39.8 million.
  • The largest annual percentage gain for Karyopharm Therapeutics' Gross Profit in the last 5 years was 8049.67% (2022), contrasted with its biggest fall of 7473.69% (2022).
  • Karyopharm Therapeutics' Gross Profit (Quarter) stood at $125.5 million in 2021, then plummeted by 74.74% to $31.7 million in 2022, then grew by 1.73% to $32.3 million in 2023, then dropped by 9.45% to $29.2 million in 2024, then grew by 11.58% to $32.6 million in 2025.
  • Its last three reported values are $32.6 million in Q4 2025, $41.9 million for Q3 2025, and $36.9 million during Q2 2025.